PT-141, also known as bremelanotide, is a synthetic cyclic peptide related to alpha-melanocyte-stimulating hormone (α-MSH). For nonclinical laboratory work, storage decisions should be based on the material’s documented form, batch information, and stability data relevant to the experiment. A universal storage temperature or shelf life cannot be established from the information supplied with this article.
This guide addresses storage documentation, sample handling, and analytical checks. It does not provide solution-preparation or administration instructions. Published findings about bremelanotide do not establish the characteristics or stability of material supplied by Alpha Carbon Labs.
Key considerations for PT-141 storage
- Identify the material: Record the batch identifier, supplied form, and any documented salt or counterion information before interpreting analytical results.
- Use documented storage conditions: Consult the batch documentation and the laboratory’s approved procedure rather than relying on generic peptide storage tables.
- Track environmental exposure: Record temperature excursions, light exposure, container openings, and freeze–thaw history where applicable.
- Separate appearance from analytical quality: A clear sample does not establish identity, purity, concentration, or absence of contamination.
- Verify experimental suitability: Use analytical acceptance criteria appropriate to the intended nonclinical assay. Storage conditions alone cannot guarantee reproducible results.
What documentation should accompany the material?
Review the certificate of analysis, available safety data sheet, and any batch-specific handling information. A certificate of analysis reports the tests and results it contains; it is not, by itself, evidence of sterility, long-term stability, or suitability for every experiment.
As part of laboratory quality control, distinguish chemical identity, chromatographic purity, and peptide content. These are different measurements. Do not treat a chromatographic area percentage as an independently measured mass concentration.
- Record receipt date, lot number, and container condition.
- Retain the analytical methods, reported results, and acceptance criteria available for the batch.
- Check whether storage recommendations apply to the supplied dry material or to a specifically characterized liquid sample.
- Document gaps in the available information before selecting storage conditions or interpreting experimental results.
Information about peptide synthesis provides manufacturing context, but a synthesis description does not replace batch-specific characterization or stability testing.
How should storage conditions be selected?
Dry material and liquid experimental samples require separate assessments. Evidence for one physical form, solvent system, concentration, or container cannot automatically be applied to another. Follow documented conditions supported for the material under study and record the basis for any laboratory-selected conditions.
The previous version of this article assigned refrigerated and frozen shelf lives, a 20–30-day liquid-sample storage window, and a 24–48-hour room-temperature degradation window. The supplied information does not establish those PT-141-specific limits. They should not be used as acceptance criteria or expiration periods.
| Material or event | Relevant records | Evidence needed for interpretation |
|---|---|---|
| Lyophilized material | Batch identity, packaging, moisture exposure, storage temperature, and time | Stability information for the supplied form and packaging |
| Liquid experimental sample | Sample composition, concentration, container, temperature, light exposure, and time | Stability measurements under the actual experimental conditions |
| Temperature excursion | Duration, temperature range, and prior storage history | Applicable excursion data or analytical comparison with an appropriate reference |
| Freeze–thaw exposure | Number of cycles and documented conditions | Sample-specific evidence of the effect on measured quality attributes |
Laboratory handling and exposure controls
Use the available safety data sheet and an institutional risk assessment to select protective equipment, containment, and waste procedures. Avoid skin and eye contact, inhalation of powder, and unnecessary aerosol generation. Do not assume that a research designation or a purity result means the material is nonhazardous.
Keep containers labeled and closed when not in use. Use designated laboratory storage equipment and document conditions with suitable monitoring. Limit unnecessary handling and environmental exposure, while recognizing that these precautions do not establish a specific shelf life.
Mixing history can be recorded as an experimental variable, but the supplied information does not support the claim that ordinary shaking fractures PT-141 peptide bonds. Likewise, gentle handling alone does not demonstrate preserved receptor binding or analytical integrity.
How can laboratories assess stability?
A stability assessment should define the sample, storage conditions, observation period, analytical methods, and acceptance criteria in advance. Compare stored samples with a characterized baseline using methods suitable for the attribute being measured.
- Identity: Use an appropriate identity method, such as mass spectrometry, with criteria established for the analytical task.
- Purity and degradation: A suitable chromatographic method can monitor changes in the measured profile. A new peak requires characterization before a chemical identity or degradation pathway is assigned.
- Concentration: Use a quantitative method appropriate to the sample matrix rather than inferring concentration from appearance or nominal vial content.
- Assay performance: If an in-vitro experiment measures receptor binding or signaling, assess that endpoint directly with appropriate controls. Chemical purity is not a substitute for a functional assay.
These are analytical planning considerations, not reported PT-141 stability results. No batch-specific storage study or functional dataset for Alpha Carbon Labs material was supplied with this article.
Frequently asked laboratory questions
Does refrigeration establish a usable storage period?
No. A temperature setting alone does not establish stability. A storage period requires evidence applicable to the sample composition, container, and measured endpoints.
What should happen after an undocumented temperature excursion?
Record what is known about the excursion and segregate the material pending review under the laboratory’s quality procedure. Do not assign a percentage loss or declare the sample unchanged without relevant evidence.
Does cloudiness identify the problem?
No. Visible particles or cloudiness warrant investigation but do not identify a specific cause. Conversely, clarity does not prove chemical integrity or freedom from contamination. Follow established acceptance and disposition procedures rather than relying on appearance alone.
Is freezing always acceptable or always damaging?
Neither blanket conclusion is supported by the supplied information. Evaluate freezing and freeze–thaw exposure for the particular sample system before adopting them as routine storage conditions.
Retained references
The supplied bibliography is retained unchanged below. Its inclusion does not validate the storage periods removed from this article or establish the properties of the material sold.
- Diamond, L. E., et al. (2004). 'Bremelanotide (PT-141), a melanocortin receptor agonist, in the treatment of sexual dysfunction.' International Journal of Impotence Research, 16(1), 51-59. — https://doi.org/10.1038/sj.ijir.3901139
- Kingsberg, S. A., et al. (2019). 'Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials.' Obstetrics & Gynecology, 134(5), 899-908. — https://doi.org/10.1097/AOG.0000000000003500
- Pfaus, J. G., et al. (2007). 'The melanocortin agonist bremelanotide facilitates female sexual behavior.' Proceedings of the National Academy of Sciences, 104(12), 4872-4877. — https://doi.org/10.1073/pnas.0700140104
- Mayer, J. P., & Zhang, F. (2016). 'Peptide stability and formulation in laboratory research.' Journal of Peptide Science, 22(8), 534-542. — https://doi.org/10.1002/psc.2898
- Safarík, L., et al. (2003). 'Lyophilization of peptides: Factors affecting conformational stability.' European Journal of Pharmaceutics and Biopharmaceutics, 56(3), 395-400. — https://doi.org/10.1016/S0939-6411(03)00141-8
- Wang, W. (1999). 'Instability, stabilization, and formulation of liquid protein pharmaceuticals.' International Journal of Pharmaceutics, 185(2), 129-188. — https://doi.org/10.1016/S0378-5173(99)00152-0
- Hadley, M. E., & Dorr, R. T. (2006). 'Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.' Peptides, 27(4), 921-930. — https://doi.org/10.1016/j.peptides.2005.01.029
- Cleland, J. L., et al. (1993). 'The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.' Critical Reviews in Therapeutic Drug Carrier Systems, 10(4), 307-377. — https://pubmed.ncbi.nlm.nih.gov/8120612/
Limitations: No product-specific storage life is established here. Alpha Carbon Labs materials are intended solely for nonclinical laboratory research. Published findings do not establish safety, effectiveness, approval, or suitability of the material sold for human or veterinary use.